Stem Cell Therapy Among Hot Topics at AAO 2017
A potential treatment for two eye conditions that currently have none — inherited retinal disease and dry age-related macular degeneration — will be among the most anticipated research presented at the American Academy of Ophthalmology (AAO) 2017 Annual Meeting, according to a report in Medscape.
Investigators will report the latest findings on the use of human embryonic stem cell–derived retinal pigment epithelial cells, which could restore vision to persons with Stargardt's macular dystrophy and non-neovascular (dry) macular degeneration. The US Food and Drug Administration is expected to approve this treatment within the next 2 months, so these papers are very timely.
Eye care providers will come away with "New Solutions, New Inspirations," according to the meeting's theme, said Maria M. Aaron, MD, secretary for AAO 2017 and professor of ophthalmology at Emory University School of Medicine, Atlanta, Georgia.
"'New' emphasizes the novel, late-breaking, cutting-edge courses, events and ideas that are presented at this year's meeting," Dr Aaron said. "There's something new for everyone — new techniques, research, technologies, strategies, therapies, and even new friends and connections."
"'New' also ties into the city that has experienced a renaissance over the past few years. New Orleans is one of America's most exciting cities," she added.
You must be logged in to leave a comment.